- Home
- SBFG vs UNCY Comparison
SBFG vs UNCY Comparison
Compare SBFG & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | UNCY |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 145.3M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBFG | UNCY |
|---|---|---|
| Price | $21.22 | $6.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 9.2K | ★ 405.5K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 27.33 | N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.10 | $0.45 |
| 52 Week High | $23.93 | $7.57 |
Technical Indicators
Market Signals| Indicator | SBFG | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 38.78 |
| Support Level | $20.60 | $5.90 |
| Resistance Level | $21.60 | $6.17 |
| Average True Range (ATR) | 0.53 | 0.29 |
| MACD | 0.13 | -0.09 |
| Stochastic Oscillator | 97.57 | 5.94 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.